Darling Ingredients Inc. (DAR): A Bull Case Theory
We came across a bullish thesis on Darling Ingredients Inc. on Valueinvestorsclub.com by TallGuy. In this article, we will summarize the bulls’ thesis on DAR. Darling Ingredients Inc.’s share was trading at $37.01 as of December 2nd. DAR’s trailing and forward P/E were 54.88 and 11.07 respectively according to Yahoo Finance. Copyright: mikkolem / 123RF Stock Photo Darling […]
Eli Lilly earmarks $6B for GLP-1 pill factory in Alabama
Eli Lilly will spend $6 billion to build an orforglipron factory in Huntsville, AL, the third of four new US sites the pharma giant plans to announce this year. As well as manufacturing the oral …
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1, orforglipron Company plans to create 3,450 manufacturing and construction jobs at Lilly’s ninth U.S. manufacturing site announced since 2020 INDIANAPOLIS, Dec….
Weight loss drugs fill a gap for women with hormonal disorder PCOS | REUTERS
Many women with PCOS say they struggled for years to get a diagnosis and effective treatment. Now, more are finding relief as GLP-1 prescriptions for PCOS rose over sevenfold in the US since 2021. #pcos #glp1 #novonordisk #elililly #hormonaldisorder #News #Reuters #Newsfeed Read the story here: https://reut.rs/4rGTKhD 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest […]
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions.
Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China
YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations. The post Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China appeared first on MedCity News.
Looming GLP-1 drug patent expirations draw generics firms
India and China are among the countries where knockoffs of Wegovy and Ozempic can be sold next year
GLP-1s may not affect obesity-related cancer risk: Study
A new study from researchers at Cambridge, Mass.-based Harvard University found that blockbuster GLP-1 drugs such as Ozempic and Zepbound may have a minimal effect on an individual’s risk of developing obesity-related cancers. The study, published Dec. 9 in Annals of Internal Medicine, is based on a review of 48 randomized controlled trials involving 94,245 […]
Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes
Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes Diabetology doi: 10.3390/diabetology6120161 Authors: Scott Reule Sean Pickthorn Stefanie Worwa Areef Ishani Robert Foley Background/Objectives: In populations with type 2 diabetes mellitus (T2DM), it is unknown whether the survival benefits of glucagon-like peptide-1 receptor agonists […]
1 Major Factor Behind the Healthcare Sector’s Recent Surge
Key Points Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones. 10 stocks we like better than Eli Lilly › The healthcare sector has vastly outperformed the broader market in recent weeks. The S&P […]